Prescribing for the pregnant patient

Cleveland Clinic Journal of Medicine

Volumn 81, Issue 6, 2014, Pages 367-372

  Mehta, Niharika ^a   Chen, Kenneth ^a   Powrie, Raymond O ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMALITIES, DRUG-INDUCED; DRUG EFFECTS; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FETOMATERNAL TRANSFUSION; FETUS DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; GESTATIONAL AGE; HUMAN; PHYSIOLOGY; PREGNANCY; STANDARDS; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FETAL DEVELOPMENT; GESTATIONAL AGE; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84903890666     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.81a.13124     Document Type: Review

References (18)

1. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 2000; 23:245-253.
2. US Food and Drug Administration (FDA). Pregnancy and lactation labeling. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm. Accessed April 4, 2014.
3. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health (Larchmt) 2005; 14:104-109.
4. Clinical Teratology Website. University of Washington. http://depts.washington.edu/terisweb/teris/. Accessed April 4, 2014.
5. REPROTOX, An Online Reproductive Toxicology Resource. Reproductive Toxicology Center. www.reprotox.org. Accessed April 4, 2014.
6. REPRORISK. Micromedex, Inc. www.micromedex.com/products/reprorisk. Accessed April 4, 2014.
7. Shepard TH. Catalog of teratogenic agents. 13th ed. Baltimore, MD: Johns Hopkins University Press; 2010.
8. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
9. Koren G. Medication safety in pregnancy and breastfeeding. McGraw-Hill Professional Publishing; 2007.
10. Friedman JM, Polifka JE. Teratogenic effects of drugs: A resource for clinicians (TERIS). Baltimore, MD: Johns Hopkins University Press; 2000.
11. MotherToBaby. www.mothertobaby.org. Accessed April 4, 2014.
12. Dunlop AL, Gardiner PM, Shellhaas CS, Menard MK, McDiarmid MA. The clinical content of preconception care: the use of medications and supplements among women of reproductive age. Am J Obstet Gynecol 2008; 199(suppl 2):S367-S372.
13. Ciarkowski SL, Stalburg CM. Medication safety in obstetrics and gynecology. Clin Obstet Gynecol 2010; 53:482-499.
14. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338:1128-1137.
15. Lambert K, Holt RI. The use of insulin analogues in pregnancy. Diabetes Obes Metab 2013; 15:888-900.
16. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160:191-196.
17. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux-data on efficacy and safety in special situations. Thromb Res 2012; 129:407-417.
18. Kweder SL, Powrie RO. Prescribing in pregnancy: a practical approach. In: Powrie RO, Greene M, Camann W, editors. De Swiet's Medical disorders in Obstetric Practice. 5th ed. Hoboken, NJ: Wiley-Blackwell; 2010:633-640 .